Datasets:
HuggingFaceM4
/
DocumentVQA

Dataset card Data Studio Files
xet
 Community
2
questionId
int32
337
40.1k
question
stringlengths
11
168
question_types
listlengths
1
4
image
imagewidth (px)
200
7.07k
docId
int32
279
12.9k
ucsf_document_id
stringlengths
8
8
ucsf_document_page_no
stringclasses
160 values
answers
listlengths
1
14
1,266
What is the graphical representation about?
[ "layout" ]
558
xqjf0226
2
[ "Summary of Segment Attractiveness" ]
1,267
On what basis, the Summary of Segment Attractiveness is carried out?
[ "layout" ]
558
xqjf0226
2
[ "based on current situation & future trends", "Based on current situation & future trends.", "current situation & future trends" ]
1,268
What are the three segments indicated in the graph?
[ "layout" ]
558
xqjf0226
2
[ "Treatment Machines, Life Negotiators, Struggle for Control" ]
1,269
what is the "document storage period " article number?
[ "layout" ]
556
jpjf0226
3
[ "7", "Article 7" ]
1,270
What is the conclusion obtained from the graph?
[ "layout" ]
558
xqjf0226
2
[ "All 3 segments have consistent needs", "All 3 Segments Have Consistent Needs." ]
1,271
mention the second point listed under the article 7(document storage period)?
[ "table/list", "layout" ]
556
jpjf0226
3
[ "To be stored for ten years", "to be stored for ten years" ]
1,272
what is article 4?
[ "form", "layout" ]
557
jpjf0226
2
[ "(PRINCIPLES OF CREATING DOCUMENTS)", "principles of creating documents", "PRINCIPLES OF CREATING DOCUMENTS" ]
1,273
Semi exclusive rights in how many countries?
[ "others", "free_text" ]
580
trjf0226
2
[ "20", "20 countries" ]
1,274
what is the title of chapter 2?
[ "form", "layout" ]
557
jpjf0226
2
[ "DOCUMENT STORAGE FUNCTIONS", "document storage functions" ]
1,276
What percent is the Supply Price / Royalty Rate?
[ "form" ]
580
trjf0226
2
[ "30% SUPPLY PRICE", "30% supply price" ]
1,277
What does article 5 in this document describes?
[ "form", "layout" ]
557
jpjf0226
2
[ "(principles concerning document storage functions)", "principles concerning document storage functions" ]
1,278
what is article 6?
[ "form", "layout" ]
557
jpjf0226
2
[ "(DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE)", "duties of responsible person in charge of storage and person in charge of storage", "DUTIES OF RESPONSIBLE PERSON IN CHARGE OF STORAGE AND PERSON IN CHARGE OF STORAGE" ]
1,279
In how many countires, license to Exclusive rights are provided?
[ "form", "free_text" ]
580
trjf0226
2
[ "60", "60 COUNTRIES", "in approximately 60 countries" ]
1,280
what is the name of pediatric program?
[ "layout" ]
560
jfkf0226
1
[ "ACTOS", "ACTOS PEDIATRIC PROGRAM" ]
1,282
What is the date mentioned in this page?
[ "layout" ]
560
jfkf0226
1
[ "5 October 2006" ]
1,283
What is the title of this document?
[ "layout" ]
573
xqjf0226
8
[ "CRITICAL SUCCESS FACTORS", "Critical Success Factors" ]
1,287
What is the title of this document?
[ "layout" ]
570
ynjf0226
6
[ "Consequences of IR" ]
1,294
What is the title of this page?
[ "layout" ]
565
ynjf0226
17
[ "ACTOS PLAN OVERVIEW", "Actos plan overview" ]
1,295
which are prescibed eariler in the treatment of type 2 diabetes under the title of "critical success factors"?
[ "table/list", "free_text" ]
565
ynjf0226
17
[ "TZD'S", "TZD's" ]
1,296
What does the graph describes in this document?
[ "layout" ]
586
ynjf0226
3
[ "TZD SHARE OF ORAL MARKET", "TZD Share of Oral Market" ]
1,301
What is the Plan TZD Share for the year 2003?
[ "table/list" ]
586
ynjf0226
3
[ "19.7%" ]
1,303
Which year has 13.3% Oral share (TZD)?
[ "table/list" ]
586
ynjf0226
3
[ "2000" ]
1,304
which has a superior lipid profile(v. avandia and others) under the title of "strength/opportunities?
[ "table/list", "free_text" ]
565
ynjf0226
17
[ "ACTOS" ]
1,309
Which study's synopsis is this?
[ "layout" ]
571
jfkf0226
4
[ "Clinical Study", "clinical" ]
1,310
what is the code mentioned under the title of clinical study synopsis?
[ "layout" ]
571
jfkf0226
4
[ "01-06-TL-OPI-527" ]
1,311
When was expert advisory meeting ?
[ "table/list", "free_text" ]
571
jfkf0226
4
[ "4 OCTOBER 2006", "4 october 2006" ]
1,312
What is the title of this document?
[ "layout" ]
599
jfkf0226
3
[ "OVERVIEW OF NOVEMBER 2006 SUBMISSION", "Overview of November 2006 Submission" ]
1,313
What is the full form of PPSR?
[ "table/list", "others" ]
599
jfkf0226
3
[ "PROPOSED PEDIATRIC STUDY REQUEST", "Proposed Pediatric Study Request" ]
1,316
What study is described in the table given?
[ "table/list", "layout" ]
605
hfkf0226
7
[ "PLACEBO- CONTROLLED DOSE RANGING STUDY", "Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Study." ]
1,317
Which parameters are considered for the study(see heading of table 2)?
[ "layout" ]
605
hfkf0226
7
[ "GLYCEMIC", "Glycemic Parameters" ]
1,318
Prior to what, the patients entered an 8 week washout/run-in-period?
[ "free_text" ]
605
hfkf0226
7
[ "double-blind treatment" ]
1,320
What is the floor supply price?
[ "free_text" ]
579
trjf0226
5
[ "$0.17 / 30 mg or Takeda's cost from site of lowest cost" ]
1,321
What is the royalty adjustment if generic enters the market ?
[ "free_text" ]
579
trjf0226
5
[ "50%", "50% royalty adjustment" ]
1,322
what is the promotional trails data usage for( Lilly in exclusive) ?
[ "free_text" ]
579
trjf0226
5
[ "Split of 70/30 (Lilly in Exclusive)", "split of 70/30 (Lilly in exclusive)", "Split of 70/30" ]
1,323
What is the title mentioned in this document?
[ "layout" ]
582
xqjf0226
9
[ "CSF'S AND MARKETING OBJECTIVES", "CSF's and Marketing Objectives" ]
1,324
What is the promotional trials data usage for (semi exclusive)?
[ "free_text" ]
579
trjf0226
5
[ "50/50 in Semi-exclusive" ]
1,325
what is the name of the plan review ?
[ "layout" ]
583
ynjf0226
1
[ "MARKETING PLAN REVIEW", "Marketing plan review.", "MARKETING PLAN" ]
1,326
What is the heading of this document?
[ "layout" ]
620
yljf0226
1
[ "ACTOS FDA RESPONSE STRATEGY", "ACTOS FDA Response Strategy" ]
1,327
What is the last revision date mentioned in this document?
[ "form" ]
620
yljf0226
1
[ "August 7, 2002" ]
1,328
What is the goal of TPNA?
[ "table/list" ]
620
yljf0226
1
[ "to supply justification to support maintaining current labeling." ]
1,329
what is the first point given in table for bladder cancer alongside of clinical findings ?
[ "table/list" ]
575
trjf0226
4
[ "OBSERVED DURING PRECLINICAL STUDIES IN RATS", "observed during preclinical studies in rats" ]
1,331
Mention the year given for Actos?
[ "layout" ]
583
ynjf0226
1
[ "2004", "Actos 2004" ]
1,333
what is the percentage of TZD share in the year 2000 ?
[ "table/list" ]
584
ynjf0226
4
[ "40.3%" ]
1,335
what is Actos TRx (000s) in the year 2003 ?
[ "table/list" ]
584
ynjf0226
4
[ "9,497" ]
1,337
how much percent of drug quantity present in rezulin under the title of 'clinical findings'?
[ "table/list" ]
575
trjf0226
4
[ "1.7%", "1.7" ]
1,339
what is the percentage of plan TZD share in the year 2004 ?
[ "table/list" ]
584
ynjf0226
4
[ "42.9%" ]
1,340
how much percent of placebo present in avandia alongside of the clinical findings?
[ "table/list" ]
575
trjf0226
4
[ "0.20%", "0.20" ]
1,341
in which month and the year the launch of Merck's PPAR's took place?
[ "figure/diagram", "others" ]
584
ynjf0226
4
[ "FEB 2005", "feb 2005" ]
1,342
what is the TZD's TRx (000s) in the year 2005 ?
[ "table/list" ]
584
ynjf0226
4
[ "22,902" ]
1,343
what is the total number of all claims under the title of "summary of litigation risk in the ous territories"?
[ "table/list" ]
575
trjf0226
4
[ "10" ]
1,344
what is the first TZD used for type 2 patients ?
[ "table/list", "free_text" ]
585
ynjf0226
13
[ "ACTOS", "Actos" ]
1,345
For which type of diabetes the TZD's prescribed earlier in treatment?
[ "table/list", "free_text" ]
585
ynjf0226
13
[ "Type 2 diabetes" ]
1,346
what has to be establish as the the best OAD medication by treating insulin resistance ?
[ "free_text" ]
585
ynjf0226
13
[ "ACTOS", "Actos" ]
1,347
What is the Specific example given?
[ "form" ]
544
gmjf0226
2
[ "pioglitazone: need to commit to studies to investigate certain signals", "Pioglitazone: Need to commit to studies to investigate certain signals" ]
1,348
what is the month and year of overview of submission ?
[ "layout" ]
588
jfkf0226
2
[ "NOVEMBER 2006", "November 2006" ]
1,349
Which country would have similar interest as in Europe?
[ "free_text" ]
544
gmjf0226
2
[ "usa", "USA" ]
1,350
what is included in the summary document ?
[ "others", "table/list", "free_text" ]
588
jfkf0226
2
[ "includes benefit-risk assessment", "benefit risk assessment", "(includes benefit-risk assessment)" ]
1,351
What is the Suggestion from Glyn?
[ "form" ]
544
gmjf0226
2
[ "tgrd would formulate direct risk management plan and obtain japan's input", "TGRD would formulate direct Risk Management plan and obtain Japan's input" ]
1,352
what is the executive summary of bladder cancer cases ?
[ "table/list" ]
588
jfkf0226
2
[ "CONFIRM" ]
1,353
Full form of PEM?
[ "free_text" ]
544
gmjf0226
2
[ "prescription event monitoring" ]
1,354
what is the name of the request document ?
[ "table/list", "layout" ]
588
jfkf0226
2
[ "PARTIAL CLINICAL HOLD REMOVAL REQUEST DOCUMENT", "Partial clinical hold removal request document", "PARTIAL CLINICAL HOLD REMOVAL" ]
1,356
who appointed as the responsible person on this issue ?
[ "table/list", "free_text" ]
594
ymjf0226
1
[ "MR. SAITO", "Mr. Saito" ]
1,357
On the purpose of teleconference, how many topics were to be discussed?
[ "layout" ]
545
fsjf0226
1
[ "3", "3 topics" ]
1,358
basically by whom the current action plan was approved ?
[ "table/list", "free_text" ]
594
ymjf0226
1
[ "CEO" ]
1,359
What is the date mentioned at the bottom?
[ "layout" ]
545
fsjf0226
1
[ "09/18/12" ]
1,360
in which month and date it was reported to CEO ?
[ "table/list", "free_text" ]
594
ymjf0226
1
[ "AUGUST 6", "August 6" ]
1,361
What is the heading of this document, given at the top?
[ "layout" ]
596
ynjf0226
5
[ "Avandamet Uptake" ]
1,362
What are shown on the x-axis?
[ "figure/diagram", "layout" ]
596
ynjf0226
5
[ "FULL MONTHS POST LAUNCH", "Full Months Post Launch" ]
1,363
what has to be reported to CEO on August 20 (japan time) ?
[ "table/list", "free_text" ]
594
ymjf0226
1
[ "AN OUTLINE OF THE FDA RESPONSE", "an outline of the FDA response" ]
1,364
What is the percentage of Avandamet scripts from Actos mentioned?
[ "figure/diagram", "layout" ]
596
ynjf0226
5
[ "36%", "36" ]
1,365
what is the name of the policy on Actos issue ?
[ "layout" ]
594
ymjf0226
1
[ "TAKEDA BASIC POLICY", "Takeda basic policy" ]
1,366
What is on the horizonal axis of the graph?
[ "figure/diagram" ]
596
ynjf0226
5
[ "Full Months Post Launch" ]
1,367
Heading of the document?
[ "layout" ]
597
ynjf0226
7
[ "LINK BETWEEN IR AND CVD", "Link between IR and CVD" ]
1,369
who is the chief leader ?
[ "table/list" ]
598
ymjf0226
2
[ "MR. K SAITO", "Mr.K Saito" ]
1,370
What is the percentage of Nondiabetic patients with prior MI?
[ "figure/diagram" ]
597
ynjf0226
7
[ "18.8%", "18.8" ]
1,371
who is the responsible person for TPNA ?
[ "table/list" ]
598
ymjf0226
2
[ "Dr. C Thom" ]
1,373
what is the name of the organization ?
[ "layout" ]
598
ymjf0226
2
[ "ACTOS ISSUE ORGANIZATION", "Actos issue organization" ]
1,374
who is the responsible person of TCI ?
[ "table/list" ]
598
ymjf0226
2
[ "MR. K SAITO" ]
1,375
What is the Handwritten sentence on the top?
[ "handwritten", "layout" ]
600
trjf0226
1
[ "Row-Contract (as of 7/19/99)" ]
1,376
What is the date mentioned?
[ "layout" ]
600
trjf0226
1
[ "JULY 19, 1999", "July 19, 1999" ]
1,377
who is the first contact person of EuR&D ?
[ "table/list" ]
598
ymjf0226
2
[ "DR. P COLLETT", "Dr. P Collett" ]
1,378
With whom is the discussion being held?
[ "layout" ]
600
trjf0226
1
[ "JIM HARPER", "Jim Harper" ]
1,380
who is the responsible person for EuR&D ?
[ "table/list" ]
598
ymjf0226
2
[ "DR. D ECKLAND", "Dr. D Eckland" ]
1,381
What is the date of randomisation?
[ "form" ]
602
rljf0226
3
[ "05-11-01", "05/11/01" ]
1,382
who is the first contact person of TPNA ?
[ "table/list" ]
598
ymjf0226
2
[ "MS. M RAMSTACK, MS. J HASKINS", "Ms. M Ramstack ,Ms. J Haskins" ]
1,383
What is the patient number?
[ "form" ]
602
rljf0226
3
[ "014" ]
1,384
What is the Centre number?
[ "form" ]
602
rljf0226
3
[ "49013" ]
1,385
who is the first contact person of TCI ?
[ "table/list" ]
598
ymjf0226
2
[ "MR. M MIYAZAKI", "Mr. M Miyazaki" ]
1,386
What is the Reference mentioned here?
[ "form" ]
602
rljf0226
3
[ "135037-HRT-11", "135037-hrt-11" ]
1,387
What is the heading of the table?
[ "layout" ]
604
hfkf0226
13
[ "Weight Changes (kg) from Baseline during Double-Blind Clinical Trials with ACTOS" ]
1,388
what is the total number of drug claims under the title of "summary of litigation risk in the ous territories"?
[ "table/list" ]
575
trjf0226
4
[ "5" ]
1,389
what are secondary endpoints ?
[ "form" ]
606
fzjf0226
7
[ "CARDIOVASCULAR MORTALITY", "cardiovascular mortality" ]
1,390
what is the title of this page?
[ "layout" ]
608
rnjf0226
4
[ "OBJECTIVES AND METHODOLOGY", "objectives and methodology" ]
1,391
What is the number of patients ?
[ "form" ]
606
fzjf0226
7
[ "5,000" ]
1,392
What is "FPV" ?
[ "form" ]
606
fzjf0226
7
[ "JUNE 2001", "June 2001" ]
1,393
What is the ACTOS 15 mg of Monotherapy?
[ "table/list" ]
604
hfkf0226
13
[ "0.9(-0.5/3.4) N=79", "0.9(-0.5/3.4) n=79" ]
1,395
What is the trial duration mentioned?
[ "table/list", "layout" ]
604
hfkf0226
13
[ "16 TO 26 WEEKS", "16 to 26 weeks" ]
1,396
what is the name of the form ?
[ "layout" ]
610
rljf0226
2
[ "URGENT DATA ENQUIRY FORM", "urgent data enquiry form", "URGENT DATA ENQUIRY" ]
1,397
what is the centre number ?
[ "form" ]
610
rljf0226
2
[ "49013" ]
1,398
What is the ACTOS 45 mg of Combination Therapy of Insulin?
[ "table/list" ]
604
hfkf0226
13
[ "4.1 (1.4/6.8) N=338", "4.1 (1.4/6.8) N=338" ]